Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3272405 | Journal de Gynécologie Obstétrique et Biologie de la Reproduction | 2014 | 9 Pages |
Abstract
To perform papsmear before 25Â years because the patient has associated high risk HPV co-factors does not appear justified by the severity or frequency of cytological lesions, especially as it increases the financial cost and is responsible of potential deleterious actions such as conizations probably excessive among the youngest patients. Personalized monitoring of these patients with a pathological papsmear is required. The French practice recommendations on cervical cancer screening (first screening at age 25, 26Â years cytological control then every 3Â years up to 65Â years in patients who have or have had sex) deserve to be applied in young and disadvantaged patients.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
B. Doris, L. Boyer, V. Lavoué, F. Riou, S. Henno, P. Tas, L. Sévène, J. Levêque,